Assembly Biosciences (ASMB) Projected to Post Quarterly Earnings on Thursday

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) is expected to announce its Q4 2024 earnings results before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($1.75) per share and revenue of $7.05 million for the quarter.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, topping analysts' consensus estimates of ($1.75) by $0.18. The business had revenue of $7.36 million for the quarter, compared to analyst estimates of $7.05 million. Assembly Biosciences had a negative return on equity of 121.46% and a negative net margin of 144.05%. On average, analysts expect Assembly Biosciences to post $-7 EPS for the current fiscal year and $-8 EPS for the next fiscal year.

Assembly Biosciences Price Performance

ASMB stock traded up $0.32 during midday trading on Friday, reaching $11.01. 25,952 shares of the stock were exchanged, compared to its average volume of 24,450. The stock has a market capitalization of $69.98 million, a PE ratio of -1.64 and a beta of 0.62. Assembly Biosciences has a 52 week low of $10.27 and a 52 week high of $19.93. The company has a fifty day moving average price of $12.91 and a 200 day moving average price of $15.14.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "neutral" rating on shares of Assembly Biosciences in a research report on Friday, December 27th.

Remove Ads

Insider Buying and Selling at Assembly Biosciences

In related news, Director Michael Houghton purchased 3,202 shares of Assembly Biosciences stock in a transaction on Monday, December 30th. The shares were purchased at an average price of $15.61 per share, for a total transaction of $49,983.22. Following the transaction, the director now owns 3,202 shares of the company's stock, valued at approximately $49,983.22. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 5.10% of the company's stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.